Tvardi data validates prodrug design, PD target engagement; plans Phase 2 in dermatologic, GI
Positive TTI-109 Phase 1 data drives 75% TVRD surge
- Tvardi announced Phase 1 results for next-gen STAT3 inhibitor TTI-109 (prodrug of TTI-101) on July 7 2026
- Study confirmed rapid conversion to active drug within 2 hours and equivalent exposure at molar-equivalent doses
- Demonstrated sustained dose-proportional PK above STAT3 IC50 with improved tolerability vs parent compound
- Reported up to 60% reductions in STAT3-driven immune cells including Th17 Tfh and B cells
- Diarrhea duration markedly shorter (0.46 vs 3.35 days) supporting better safety profile
- Data validates prodrug design and PD target engagement; plans Phase 2 in dermatologic and GI diseases
- Webcast held at 8:30am ET same day to discuss results aligns with anticipated catalyst from prior updates
- Stock closed near $2.01 on July 6 before surging on the news
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.